發(fā)布時(shí)間：2018-01-19 00:34

  本文關(guān)鍵詞： 肝炎病毒 乙型 肝炎核心杭原 乙型 樹突狀細(xì)胞 脂質(zhì)體 轉(zhuǎn)染　出處：《南京醫(yī)科大學(xué)》2006年碩士論文　論文類型：學(xué)位論文

【摘要】：乙型肝炎病毒(hepatitis B virus HBV)感染是一個(gè)世界范圍內(nèi)的高感染率、高危害性的疾�。喝蚣s有3.5億HBV感染者，僅我國乙肝病毒感染率就達(dá)約60-70％，其中15-25％感染者最終會(huì)死于HBV相關(guān)性疾病，這使得HBV感染成為危害人類最嚴(yán)重的疾病之一。 目前，抗乙肝病毒的主要治療藥物為干擾素和核苷類似物拉米夫定等，，但是由于二者均不能消除病毒復(fù)制模板共價(jià)閉合環(huán)狀DNA(cccDNA)的存在，故停藥后病情仍會(huì)反復(fù)。因此對于慢性HBV感染治療上的深入研究有著極強(qiáng)的現(xiàn)實(shí)意義。 現(xiàn)有的研究發(fā)現(xiàn)在持續(xù)性HBV感染的發(fā)病機(jī)制中，特異性細(xì)胞免疫能力的低下或不足起著至關(guān)重要的作用，而樹突裝細(xì)胞(DC)作為目前已知的人體內(nèi)最強(qiáng)大的抗原遞呈細(xì)胞，機(jī)體免疫反應(yīng)的始動(dòng)者，通過參與抗原的攝取加工與遞呈，對誘導(dǎo)免疫應(yīng)答起著關(guān)鍵性的作用，與慢性乙型肝炎的發(fā)病機(jī)理和治療都有十分緊密的聯(lián)系。以DC為基礎(chǔ)的免疫治療正成為慢性HBV感染研究的新方向。 既往研究證實(shí)慢乙肝患者的DC存在成熟與功能的異常，導(dǎo)致其激活特異性抗病毒免疫反應(yīng)特別是細(xì)胞免疫反應(yīng)能力低下。因此，恢復(fù)慢性乙型肝炎患者DC的功能以增強(qiáng)其激活特異性抗HBV免疫反應(yīng)能力，則可能達(dá)到打破免疫耐受，徹底清除HBV的作用。要保持高水平的持久的抗病毒免疫效應(yīng)需要以致敏的DC反復(fù)刺激機(jī)體。為了使DC
[Abstract]:Hepatitis B virus virus (HBV) infection is a worldwide high infection rate, a highly harmful disease: there are about 350 million HBV infections worldwide. The infection rate of hepatitis B virus in China is about 60-70%, among which 15-25% of the infected people will eventually die from HBV related diseases, which makes HBV infection become one of the most serious diseases that harm human beings. At present, the main anti-HBV drugs are interferon and nucleoside analogues lamivudine and so on. But neither of them can eliminate the existence of viral replication template covalently closed circular DNA (cccDNAs). Therefore, the treatment of chronic HBV infection is of great practical significance. Existing studies have found that the low or deficiency of specific cellular immunity plays a crucial role in the pathogenesis of persistent HBV infection. As the most powerful antigen-presenting cells in human body, dendritic cells (DCCs) are the initiators of immune response, which are involved in antigen uptake and presentation. It plays a key role in inducing immune response and is closely related to the pathogenesis and treatment of chronic hepatitis B. Immunotherapy based on DC is becoming a new direction in the study of chronic HBV infection. Previous studies have confirmed that DC in patients with chronic hepatitis B has abnormal maturation and function, resulting in its activation of specific antiviral immune response, especially the ability of cellular immune response is low. Restoring the function of DC in patients with chronic hepatitis B to enhance its ability to activate specific anti HBV immune response may break the immune tolerance. Remove the effect of HBV completely. To maintain a high level of persistent antiviral immune effect, it is necessary for sensitive DC to repeatedly stimulate the body. In order to make DC
【學(xué)位授予單位】：南京醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2006
【分類號(hào)】：R392

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 樊代明;;消化病 幾多“是”中幾多“非”[J];醫(yī)學(xué)爭鳴;2010年02期

2 宋駿;夏長勝;;皖南地區(qū)乙型肝炎病毒基因型和亞型的分布特征[J];皖南醫(yī)學(xué)院學(xué)報(bào);2011年04期

3 余瑞芳;劉亞;劉懷印;;2004—2010年商丘市丙肝流行病學(xué)分析[J];河南預(yù)防醫(yī)學(xué)雜志;2011年04期

4 ;看點(diǎn)[J];家庭之友(愛侶);2011年09期

5 邵愛東;張彥;;147例丙型病毒性肝炎臨床治療回顧性分析[J];中國醫(yī)藥導(dǎo)報(bào);2011年23期

6 陳s

本文編號(hào)：1441893